Novartis has acquired Kate Therapeutics for up to $1.1 billion, the companies said today, in a deal that expands the buyer’s ...

Thermo Fisher has launched a suite of expanded CRO and CDMO services under its own brand, Accelerator™ Drug Development, ...

Researchers suggest broadly reactive antibodies identified are likely to represent a common mechanism of acquired immunity to ...

The new business combines solutions from four companies and will target customers in pharma and biotech, consumer markets, ...

For this new study, a team tested the engineered D22 compound against several priority bacterial infections in animals. In ...

In this GEN webinar, experts from WuXi AppTec will share essential strategies and methodologies for accelerating pre-clinical ...

The new facility complements existing mammalian-derived product manufacturing at 6,000L and 20,000L scales provided from ...

The NATi mRNA BioFoundry is part of an ongoing effort to strengthen Singapore’s position in nucleic acid therapeutics.

Controlling the dissolved oxygen in bioreactors sets the stage for developing new treatments for liver disease.

Recursion and Exscientia, two pioneers in artificial intelligence (AI)-based drug development, have completed a business combination that they vowed will enhance their ability to carry out drug ...

Waters added Wyatt Tehnology’s light scattering instruments to their portfolio last yeaf. According to Pittman, the company ...

By understanding more about the cycle of inflammation, it might be possible to find new ways to prevent or treat this in IBD.